Israel, Oct. 25 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will present at the Oppenheimer 21st Annual Healthcare Conference in New York and the World Orphan Drug Congress 2010 in Geneva.
The conference schedule is as follows: | |
Oppenheimer 21st Annual Healthcare Conference | |
Corporate Presentation, November 2 at 12:00 PM ET | |
Waldorf Astoria Hotel, New York, NY | |
A webcast of this presentation will be available at www.protalix.comon the event calendar page | |
World Orphan Drug Congress 2010 | |
Presentation, November 30 at 9:10 AM CEST | |
Crown Plaza Hotel, Geneva, Switzerland | |
About Protalix
Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix’s ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company’s new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Investor Contact: | |
Marcy Nanus | |
The Trout Group, LLC | |
Telephone: 646-378-2927 | |
Email: mnanus@troutgroup.com | |
SOURCE Protalix BioTherapeutics, Inc.
